An approved biosimilar may not be profitable without the right market entry and commercialization plan. In part II, topics of discussion will include:

• Timing market entry with data and market exclusivity expirations
• Meeting manufacturing requirements once exclusivity is decided
• Devising strategies for achieving preferred access with managed care plans
• Managing stakeholder education
• Reconciling post market and pharmacovigilance requirements
• Mastering distribution and delivery across borders